The short answer
Watchful waiting is a real option in follicular lymphoma, and three randomized trials found no survival difference against immediate chemotherapy. When treatment is needed, rituximab is usually central, with radiation for single-site disease and CAR T or mosunetuzumab after two prior lines.
Three randomized trials comparing watchful waiting with immediate chemotherapy showed no difference in overall survival.
Radiation alone can control follicular lymphoma found in a single area for a long time.
Rituximab targets CD20 and can be given alone, with chemotherapy, or continued as maintenance every 2 to 3 months.
After two or more prior lines, CD19 CAR T-cell therapy and mosunetuzumab become options, both with a real risk of cytokine release syndrome.
Choose how you want to understand this
The full explanation.
Start with disease status and goal
Treatment for follicular lymphoma is not one-size-fits-all. It depends on how much disease you have, whether it is causing symptoms, and your overall goals. Ask your team what the goal of treatment is for you: remission, long-term control, or comfort.
Watchful waiting
Many people are diagnosed with early or slow-growing follicular lymphoma that is not causing symptoms. For them, watchful waiting is a standard option, not a delay in care. It means regular check-ins and blood work, with treatment starting only if the disease changes. Studies show that starting treatment early in this group does not improve long-term survival compared to waiting.
Radiation for limited disease
If follicular lymphoma is found in just one area, radiation alone can be an effective treatment. It targets the specific lymph node area and can control the disease for a long time in early-stage cases.
Antibody and chemotherapy combinations
When wider treatment is needed, rituximab is often central. This drug targets a protein called CD20 on lymphoma cells. It can be given alone, or combined with chemotherapy drugs such as bendamustine, or with the R-CHOP combination. After a good response, some people go on to maintenance treatment with rituximab, or a related drug called obinutuzumab, given at intervals over a period of months to years. It is meant to keep the disease controlled for longer.
Maintenance is a discussion, not a default. Several things shape it. Which induction you had. Whether this is a first or a later line. How completely the lymphoma responded. How much infection risk you already carry. And whether vaccines matter for you, since anti-CD20 drugs blunt vaccine responses for months. Plenty of people finish induction and have no maintenance at all. Ask if it is being proposed, what it should add, and what the schedule would be.
Targeted options for harder cases
For lymphoma that returns after treatment, other options exist. Lenalidomide, a drug that helps your immune system attack the lymphoma, can be paired with rituximab. Options widen for disease that has come back after two or more prior treatments. One is CD19-directed CAR T-cell therapy, using lab-engineered versions of your own immune cells. Another is mosunetuzumab, a drug that links your T cells directly to the lymphoma cells.
Weighing benefits and harms
Every option has trade-offs. Watchful waiting avoids treatment side effects but means living with known disease. Chemoimmunotherapy can control disease for years but brings infection risk, fatigue, and other side effects. CAR T-cell therapy can work well in hard-to-treat cases. But it carries risks: cytokine release syndrome, a reaction with fever and low blood pressure, and neurologic side effects. Both require close monitoring right after infusion, often near a specialized center for a few weeks.
What to ask your team
- What is the goal of my treatment: watch, control, or aim for a longer remission?
- Am I a candidate for watchful waiting right now?
- Why is this specific drug combination recommended over the others?
- Is maintenance therapy part of the plan, and for how long?
- If this treatment does not work, what would come next?
- Is a clinical trial a reasonable option for me?
When to get help sooner
- Call 911 or go to an emergency department if you get a very high fever with a sharp drop in blood pressure after CAR T-cell therapy or mosunetuzumab. Do the same if you become confused, very hard to wake, unable to speak clearly, or have a seizure. These are the signs of cytokine release syndrome and of nerve toxicity.
- Call your lymphoma team without delay, day or night, if a temperature of 100.4°F (38°C) or higher, the figure CDC uses, or shaking chills turn up while you are on rituximab, obinutuzumab, or chemotherapy. With low white cells CDC counts this as a medical emergency. If you cannot reach the team quickly, go to an emergency department and say you are on treatment for lymphoma. Ask before you take anything to bring a fever down, since it can hide the problem.
- Call your care team within a day or two if lymph nodes start growing again, you get drenching night sweats, or you lose weight without trying.
Sources
Words to know
Tap any term to see what it means.
Common questions
Is watchful waiting the same as doing nothing?
No. For people with early or slow-growing follicular lymphoma that is not causing symptoms, it is a standard option rather than a delay in care. It means regular check-ins and blood work, with treatment starting only if the disease changes. Studies show that starting treatment early in this group does not improve long-term survival compared with waiting.
What if the lymphoma is only in one area?
Radiation alone can be an effective treatment. It targets the specific lymph node area involved. In early-stage cases it can control the disease for a long time.
What does rituximab do?
It targets a protein called CD20 on lymphoma cells. It can be given alone, combined with a chemotherapy drug such as bendamustine, or with the R-CHOP combination. After a good response, some people go on to maintenance treatment with rituximab or obinutuzumab, spaced out over months. Whether that is offered, and for how long, depends on your induction, your response and your infection risk, so ask rather than assume it applies to you.
What options exist if it comes back?
Lenalidomide, a drug that helps your immune system attack the lymphoma, can be paired with rituximab. Options widen for disease that has returned after two or more prior treatments. One is CD19-directed CAR T-cell therapy, using lab-engineered versions of your own immune cells. Another is mosunetuzumab, which links your T cells directly to the lymphoma cells.
What are the trade-offs of CAR T-cell therapy?
It can work well in hard-to-treat cases, but it carries real risks. Those include cytokine release syndrome, a reaction with fever and low blood pressure, and neurologic side effects. It needs close monitoring right after infusion, often near a specialized center for a few weeks.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this guide into a short list for your care team.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-13 what this meansLast updated: 2026-08-20Next planned review: 2027-01-22
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share